<!DOCTYPE html>
<html class="client-nojs vector-feature-language-in-header-enabled vector-feature-language-in-main-page-header-disabled vector-feature-page-tools-pinned-disabled vector-feature-toc-pinned-clientpref-0 vector-toc-not-available vector-feature-main-menu-pinned-disabled vector-feature-limited-width-clientpref-1 vector-feature-limited-width-content-enabled vector-feature-custom-font-size-clientpref-1 vector-feature-appearance-pinned-clientpref-0 skin-theme-clientpref-day vector-sticky-header-enabled" lang="de" dir="ltr"><head>
<meta charset="UTF-8">
<title>CTI BioPharma</title>
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<link rel="icon" type="image/png" href="./_res_/favicon.png">
<link rel="canonical" href="https://de.wikipedia.org/wiki/CTI_BioPharma"> <link href="./_mw_/ext.cite.styles.css" rel="stylesheet" type="text/css">
<link href="./_mw_/ext.wikimediamessages.styles.css" rel="stylesheet" type="text/css">
<link href="./_mw_/skins.vector.icons.css" rel="stylesheet" type="text/css">
<link href="./_mw_/skins.vector.search.codex.styles.css" rel="stylesheet" type="text/css">
<link href="./_mw_/skins.vector.styles.css" rel="stylesheet" type="text/css">
<meta name="ResourceLoaderDynamicStyles" content="">
<link href="./_mw_/ext.gadget.citeRef.css" rel="stylesheet" type="text/css">
<link href="./_mw_/ext.gadget.defaultPlainlinks.css" rel="stylesheet" type="text/css">
<link href="./_mw_/ext.gadget.dewikiCommonHide.css" rel="stylesheet" type="text/css">
<link href="./_mw_/ext.gadget.dewikiCommonLayout.css" rel="stylesheet" type="text/css">
<link href="./_mw_/ext.gadget.dewikiCommonStyle.css" rel="stylesheet" type="text/css">
<link href="./_mw_/ext.gadget.dewikiDarkmode.css" rel="stylesheet" type="text/css">
<link href="./_mw_/ext.gadget.dewikiResponsive.css" rel="stylesheet" type="text/css">
<link href="./_mw_/ext.gadget.specialSearch.css" rel="stylesheet" type="text/css">
<link rel="stylesheet" type="text/css" href="./_mw_/site.styles.css">
<link rel="stylesheet" type="text/css" href="./_mw_/noscript.css">
<link rel="stylesheet" type="text/css" href="./_res_/footer.css">
<link rel="stylesheet" type="text/css" href="./_res_/vector-2022.css">
</head>
<body class="skin--responsive skin-vector skin-vector-search-vue mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-CTI_BioPharma rootpage-CTI_BioPharma skin-vector-2022 action-view">
<div class="mw-page-container">
<div class="mw-page-container-inner">
<div class="mw-content-container">
<main id="content" class="mw-body">
<header class="mw-body-header vector-page-titlebar">
<h1 id="firstHeading" class="firstHeading mw-first-heading"><span class="mw-page-title-main">CTI BioPharma</span></h1>
</header>
<a id="top"></a>
<div id="bodyContent" class="vector-body ve-init-mw-desktopArticleTarget-targetContainer" aria-labelledby="firstHeading" data-mw-ve-target-container="">
<div id="contentSub">
<div id="mw-content-subtitle"></div>
</div>
<div id="mw-content-text" class="mw-body-content mw-content-ltr" lang="de" dir="ltr"><div class="mw-content-ltr mw-parser-output" lang="de" dir="ltr"><table class="toccolours infobox float-right toptextcells vorlage-infobox-unternehmen" style="font-size:90%; max-width:25em; margin-top:0;" summary="Infobox Unternehmen">
<tbody><tr>
<th colspan="2" class="hintergrundfarbe5" style="font-size:110%;">CTI BioPharma
</th></tr>
<tr>
<td style="font-weight:bold;"><a href="Rechtsform" title="Rechtsform">Rechtsform</a>
</td>
<td><a href="Gesellschaftsrecht_der_Vereinigten_Staaten#Corporation" title="Gesellschaftsrecht der Vereinigten Staaten">Incorporated</a>
</td></tr>
<tr>
<td style="font-weight:bold;"><a href="Internationale_Wertpapierkennnummer" title="Internationale Wertpapierkennnummer">ISIN</a>
</td>
<td><a class="external text" href="https://iw.toolforge.org/isin?language=de&isin=US12648L6011">US12648L6011</a>
</td></tr>
<tr>
<td style="font-weight:bold;"><a href="Gr%C3%BCndung_(Recht)" title="Gründung (Recht)">Gründung</a>
</td>
<td><a href="1992" title="1992">1992</a><sup id="cite_ref-History_1-0" class="reference"><a href="#cite_note-History-1"><span class="cite-bracket">[</span>1<span class="cite-bracket">]</span></a></sup>
</td></tr>
<tr>
<td style="font-weight:bold;"><a href="Sitz_(juristische_Person)" title="Sitz (juristische Person)">Sitz</a>
</td>
<td><a href="Seattle" title="Seattle">Seattle</a>, <a href="Washington_(Bundesstaat)" title="Washington (Bundesstaat)">WA</a> <a href="Vereinigte_Staaten_von_Amerika" class="mw-redirect" title="Vereinigte Staaten von Amerika">USA</a><sup id="cite_ref-contact_2-0" class="reference"><a href="#cite_note-contact-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup>
</td></tr>
<tr>
<td style="font-weight:bold;"><a href="Unternehmensf%C3%BChrung" title="Unternehmensführung">Leitung</a>
</td>
<td>Adam R. Craig, <a href="CEO" class="mw-redirect" title="CEO">CEO</a>, Jack W. Singer, Gründer und <a href="Vizepr%C3%A4sident#Wirtschaft" title="Vizepräsident">EVP</a><sup id="cite_ref-3" class="reference"><a href="#cite_note-3"><span class="cite-bracket">[</span>3<span class="cite-bracket">]</span></a></sup>
</td></tr>
<tr>
<td style="font-weight:bold;"><a href="Erl%C3%B6s" title="Erlös">Umsatz</a>
</td>
<td>57,4 Mio. US-Dollar (2016)<sup id="cite_ref-2016financials_4-0" class="reference"><a href="#cite_note-2016financials-4"><span class="cite-bracket">[</span>4<span class="cite-bracket">]</span></a></sup>
</td></tr>
<tr>
<td style="font-weight:bold;"><a href="Wirtschaftszweig" title="Wirtschaftszweig">Branche</a>
</td>
<td><a href="Pharmazie" title="Pharmazie">Pharmazie</a>
</td></tr>
<tr>
<td style="font-weight:bold;">Website
</td>
<td><a rel="nofollow" class="external text" href="http://www.ctibiopharma.com">www.ctibiopharma.com</a>
</td></tr></tbody></table><div class="editoronly" style="display:none;"></div>
<p><b>CTI BioPharma</b> ist ein US-amerikanisches, biotechnologisches Pharmaunternehmen, das 1992 als CTI gegründet wurde und seit 1997 an der amerikanischen Technologiebörse <a href="NASDAQ" class="mw-redirect" title="NASDAQ">NASDAQ</a> unter dem Kennzeichen CTIC gelistet ist.<sup id="cite_ref-History_1-1" class="reference"><a href="#cite_note-History-1"><span class="cite-bracket">[</span>1<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-FAQ_5-0" class="reference"><a href="#cite_note-FAQ-5"><span class="cite-bracket">[</span>5<span class="cite-bracket">]</span></a></sup> Seinen Hauptsitz hat in CTI BioPharma <a href="Seattle" title="Seattle">Seattle</a>, <a href="Washington_(Bundesstaat)" title="Washington (Bundesstaat)">Washington</a>.<sup id="cite_ref-contact_2-1" class="reference"><a href="#cite_note-contact-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup> Das Unternehmen ist spezialisiert auf die <a href="Unternehmenskauf" title="Unternehmenskauf">Akquisition</a>, Entwicklung und Vermarktung von neuen zielgerichteten Therapien, in erster Linie in der <a href="H%C3%A4matologie" title="Hämatologie">Hämatologie</a>.<sup id="cite_ref-6" class="reference"><a href="#cite_note-6"><span class="cite-bracket">[</span>6<span class="cite-bracket">]</span></a></sup>
</p>
<div class="mw-heading mw-heading2"><h2 id="Medikamente">Medikamente</h2></div>
<p>CTI BioPharma hat folgende Medikamente im Markt:
</p>
<ul><li>Pixantron (Handelsname in der EU: <i>Pixuvri</i>; in den USA nicht zugelassen)<sup id="cite_ref-7" class="reference"><a href="#cite_note-7"><span class="cite-bracket">[</span>7<span class="cite-bracket">]</span></a></sup> zur Behandlung von erwachsenen Patienten mit bestimmten Formen des <a href="Non-Hodgkin-Lymphom" title="Non-Hodgkin-Lymphom">Non-Hodkin-B-Zell-Lymphoms</a>.<sup id="cite_ref-8" class="reference"><a href="#cite_note-8"><span class="cite-bracket">[</span>8<span class="cite-bracket">]</span></a></sup> <i>Pixuvri</i> wird in allen Märkten außerhalb der USA von <a href="Servier" title="Servier">Servier</a> vermarktet.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li>
<li><a href="Pacritinib" title="Pacritinib">Pacritinib</a> (Handelsname in den USA: <i>Vonjo</i>; bisher nur dort zugelassen)<sup id="cite_ref-10" class="reference"><a href="#cite_note-10"><span class="cite-bracket">[</span>10<span class="cite-bracket">]</span></a></sup>, ein Janus Kinase Inhibitor zur Therapie der <a href="Myelofibrose" class="mw-redirect" title="Myelofibrose">Myelofibrose</a> und <a href="Thrombozytopenie" title="Thrombozytopenie">Thrombozytopenie</a>.</li></ul>
<p>Folgende Substanzen befinden sich in der (weiteren) klinischen Entwicklung:<sup id="cite_ref-11" class="reference"><a href="#cite_note-11"><span class="cite-bracket">[</span>11<span class="cite-bracket">]</span></a></sup>
</p>
<ul><li>Pixantron in einer anderen Form des <a href="Non-Hodgkin-Lymphom#Notwendigkeit_einer_einheitlichen_Klassifikation_der_Non-Hodgkin-Lymphome" title="Non-Hodgkin-Lymphom">NHL</a>.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12"><span class="cite-bracket">[</span>12<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-13" class="reference"><a href="#cite_note-13"><span class="cite-bracket">[</span>13<span class="cite-bracket">]</span></a></sup></li>
<li>Tosedostat, ein selektiver, oraler Inhibitor der <a href="Aminopeptidasen" title="Aminopeptidasen">Aminopeptidasen</a> in rezidivierenden / refraktären <a href="Akute_myeloische_Leuk%C3%A4mie" title="Akute myeloische Leukämie">AML</a> / <a href="Myelodysplastisches_Syndrom" title="Myelodysplastisches Syndrom">MDS</a>.</li></ul>
<div class="mw-heading mw-heading2"><h2 id="Kooperationen">Kooperationen</h2></div>
<p>CTI BioPharma richtet sich strategisch stark auf Kooperationen aus.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14"><span class="cite-bracket">[</span>14<span class="cite-bracket">]</span></a></sup>
</p>
<ul><li>Seit 2014 kooperiert CTI BioPharma mit dem französischen Pharmaunternehmen <a href="Servier" title="Servier">Servier</a> zur Vermarktung von <i>Pixuvri</i> in Europa.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15"><span class="cite-bracket">[</span>15<span class="cite-bracket">]</span></a></sup></li>
<li>Im Juni 2017 erhielt CTI BioPharma von dem israelischen Pharmaunternehmen <a href="Teva" title="Teva">Teva</a> ein <i>milestone payment</i> in Höhe von 10 Mio. $ aufgrund der Erreichung von Meilensteinen in den Verkaufszahlen von <i>Trisenox</i> (<a href="Arsen(III)-oxid" title="Arsen(III)-oxid">Arsen(III)-oxid</a>), einem Medikament, das CTI BioPharma seinerzeit an das – zwischenzeitlich von Teva gekaufte – Pharmaunternehmen <a href="Cephalon_(Unternehmen)" title="Cephalon (Unternehmen)">Cephalon</a> verkauft hat.<sup id="cite_ref-16" class="reference"><a href="#cite_note-16"><span class="cite-bracket">[</span>16<span class="cite-bracket">]</span></a></sup> <i>Trisenox</i> hat in Europa den Status eines <a href="Orphan-Arzneimittel" title="Orphan-Arzneimittel">Orphan-Arzneimittels</a> und wird zur Behandlung der akuten <a href="Promyelozytenleuk%C3%A4mie" title="Promyelozytenleukämie">Promyelozytenleukämie</a> (APL), einer Unterform der <a href="Akute_myeloische_Leuk%C3%A4mie" title="Akute myeloische Leukämie">akuten myeloischen Leukämie</a>, eingesetzt.<sup id="cite_ref-17" class="reference"><a href="#cite_note-17"><span class="cite-bracket">[</span>17<span class="cite-bracket">]</span></a></sup> Weitere 10 Mio. $ als <i>milestone payment</i> erwartete CTI BioPharma von Teva für <i>Trisenox</i> im Februar 2018.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18"><span class="cite-bracket">[</span>18<span class="cite-bracket">]</span></a></sup></li></ul>
<div class="mw-heading mw-heading2"><h2 id="Weblinks">Weblinks</h2></div>
<ul><li><a rel="nofollow" class="external text" href="http://www.ctibiopharma.com">WebSite der CTI BioPharma Inc.</a></li>
<li><a rel="nofollow" class="external text" href="http://www.finanzen.net/aktien/CTI_BioPharma_1-Aktie">CTI BioPharma Aktie</a></li></ul>
<div class="mw-heading mw-heading2"><h2 id="Einzelnachweise">Einzelnachweise</h2></div>
<ol class="references">
<li id="cite_note-History-1"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-History_1-0">a</a></sup> <sup><a href="#cite_ref-History_1-1">b</a></sup></span> <span class="reference-text"><style data-mw-deduplicate="TemplateStyles:r261891140">
/* start https://de.wikipedia.org/ */
.mw-parser-output .webarchiv-memento a{color:inherit}
/* end https://de.wikipedia.org/ */
</style><a rel="nofollow" class="external text" href="https://web.archive.org/web/20170518184103/http://www.ctibiopharma.com/about-us/historical-timeline/">History</a> (<span class="webarchiv-memento"><a href="Webarchivierung#Begrifflichkeiten" title="Webarchivierung">Memento</a></span> vom 18. Mai 2017 im <i><a href="Internet_Archive" title="Internet Archive">Internet Archive</a></i>), Company WebSite, abgerufen am 23. Mai 2017</span>
</li>
<li id="cite_note-contact-2"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-contact_2-0">a</a></sup> <sup><a href="#cite_ref-contact_2-1">b</a></sup></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20170510050903/http://www.ctibiopharma.com/about-us/contact-cti/">CTI BioPharma Global Headquarters</a> (<span class="webarchiv-memento"><a href="Webarchivierung#Begrifflichkeiten" title="Webarchivierung">Memento</a></span> vom 10. Mai 2017 im <i><a href="Internet_Archive" title="Internet Archive">Internet Archive</a></i>), Company WebSite, abgerufen am 23. Mai 2017</span>
</li>
<li id="cite_note-3"><span class="mw-cite-backlink"><a href="#cite_ref-3">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20170510050907/http://www.ctibiopharma.com/about-us/management/">About us, Management</a> (<span class="webarchiv-memento"><a href="Webarchivierung#Begrifflichkeiten" title="Webarchivierung">Memento</a></span> vom 10. Mai 2017 im <i><a href="Internet_Archive" title="Internet Archive">Internet Archive</a></i>), Company WebSite, abgerufen am 23. Mai 2017</span>
</li>
<li id="cite_note-2016financials-4"><span class="mw-cite-backlink"><a href="#cite_ref-2016financials_4-0">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2251181">CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results</a><span style="display:none"><a rel="nofollow" class="external text" href="http://deadurl.invalid/http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2251181">@1</a></span><span style="display:none"><a rel="nofollow" class="external text" href="http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2251181">@2</a></span><span style="display:none">Vorlage:Toter Link/investors.ctibiopharma.com</span> <small>(Seite dauerhaft nicht mehr abrufbar, festgestellt im Dezember 2023. <a rel="nofollow" class="external text" href="http://timetravel.mementoweb.org/list/2010/http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2251181">Suche in Webarchiven</a>)</small>, PM CTI BioPharma vom 2. März 2017, abgerufen am 23. Mai 2017</span>
</li>
<li id="cite_note-FAQ-5"><span class="mw-cite-backlink"><a href="#cite_ref-FAQ_5-0">↑</a></span> <span class="reference-text"> <a rel="nofollow" class="external text" href="http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=irol-faq">Investor FAQ</a>, Company WebSite, abgerufen am 23. Mai 2017</span>
</li>
<li id="cite_note-6"><span class="mw-cite-backlink"><a href="#cite_ref-6">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=irol-irhome">Overview</a>, Company WebSite, abgerufen am 23. Mai 2017</span>
</li>
<li id="cite_note-7"><span class="mw-cite-backlink"><a href="#cite_ref-7">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20170508193419/http://www.ctibiopharma.com/products/pixuvri/">Approved in the EU</a> (<span class="webarchiv-memento"><a href="Webarchivierung#Begrifflichkeiten" title="Webarchivierung">Memento</a></span> vom 8. Mai 2017 im <i><a href="Internet_Archive" title="Internet Archive">Internet Archive</a></i>), Company WebSite, abgerufen am 23. Mai 2017</span>
</li>
<li id="cite_note-8"><span class="mw-cite-backlink"><a href="#cite_ref-8">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Summary_for_the_public/human/002055/WC500127971.pdf">Zusammenfassung des EPAR für die Öffentlichkeit</a>, European Medicines Agency (EMA), abgerufen am 23. Mai 2017</span>
</li>
<li id="cite_note-9"><span class="mw-cite-backlink"><a href="#cite_ref-9">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20170812135010/http://servier-oncology.com/servier-cti-biopharma-expand-license-collaboration-agreement-develop-commercialize-pixuvri/">Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI®</a> (<span class="webarchiv-memento"><a href="Webarchivierung#Begrifflichkeiten" title="Webarchivierung">Memento</a></span> vom 12. August 2017 im <i><a href="Internet_Archive" title="Internet Archive">Internet Archive</a></i>), PM Servier vom 25. April 2017, abgerufen am 26. Mai 2017</span>
</li>
<li id="cite_note-10"><span class="mw-cite-backlink"><a href="#cite_ref-10">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20220301081430/https://investors.ctibiopharma.com/news-releases/news-release-details/cti-biopharma-announces-fda-accelerated-approval-vonjotm">Archivierte Kopie</a> (<span class="webarchiv-memento"><a href="Webarchivierung#Begrifflichkeiten" title="Webarchivierung">Memento</a></span> vom 1. März 2022 im <i><a href="Internet_Archive" title="Internet Archive">Internet Archive</a></i>)</span>
</li>
<li id="cite_note-11"><span class="mw-cite-backlink"><a href="#cite_ref-11">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20170202235057/http://www.ctibiopharma.com/pipeline/">Company-Sponsored Trials</a> (<span class="webarchiv-memento"><a href="Webarchivierung#Begrifflichkeiten" title="Webarchivierung">Memento</a></span> vom 2. Februar 2017 im <i><a href="Internet_Archive" title="Internet Archive">Internet Archive</a></i>), Company WebSite, abgerufen am 23. Mai 2017</span>
</li>
<li id="cite_note-12"><span class="mw-cite-backlink"><a href="#cite_ref-12">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.ctibiopharma.com/pipeline/pacritinib/">About Pacritinib</a>, Company WebSite, abgerufen am 4. Februar 2018</span>
</li>
<li id="cite_note-13"><span class="mw-cite-backlink"><a href="#cite_ref-13">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2328587">Extension granted by CHMP of the EMA for response to Day 120 List of Questions for the MAA for pacritinib</a><span style="display:none"><a rel="nofollow" class="external text" href="http://deadurl.invalid/http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2328587">@1</a></span><span style="display:none"><a rel="nofollow" class="external text" href="http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2328587">@2</a></span><span style="display:none">Vorlage:Toter Link/investors.celltherapeutics.com</span> <small>(Seite dauerhaft nicht mehr abrufbar, festgestellt im Dezember 2023. <a rel="nofollow" class="external text" href="http://timetravel.mementoweb.org/list/2010/http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2328587">Suche in Webarchiven</a>)</small>, PM CTI BioPharma vom 25. Januar 2018, abgerufen am 4. Februar 2018</span>
</li>
<li id="cite_note-14"><span class="mw-cite-backlink"><a href="#cite_ref-14">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20170518184757/http://www.ctibiopharma.com/about-us/collaborations/">Partnering with CTI BioPharma</a> (<span class="webarchiv-memento"><a href="Webarchivierung#Begrifflichkeiten" title="Webarchivierung">Memento</a></span> vom 18. Mai 2017 im <i><a href="Internet_Archive" title="Internet Archive">Internet Archive</a></i>)</span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><a href="#cite_ref-15">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2264222">Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI®</a><span style="display:none"><a rel="nofollow" class="external text" href="http://deadurl.invalid/http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2264222">@1</a></span><span style="display:none"><a rel="nofollow" class="external text" href="http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2264222">@2</a></span><span style="display:none">Vorlage:Toter Link/investors.ctibiopharma.com</span> <small>(Seite dauerhaft nicht mehr abrufbar, festgestellt im Dezember 2023. <a rel="nofollow" class="external text" href="http://timetravel.mementoweb.org/list/2010/http://investors.ctibiopharma.com/phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2264222">Suche in Webarchiven</a>)</small>, PM CTI BioPharma vom 25. April 2017, abgerufen am 23. Mai 2017</span>
</li>
<li id="cite_note-16"><span class="mw-cite-backlink"><a href="#cite_ref-16">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=RssLanding&cat=news&id=2281044">CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®</a><span style="display:none"><a rel="nofollow" class="external text" href="http://deadurl.invalid/http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=RssLanding&cat=news&id=2281044">@1</a></span><span style="display:none"><a rel="nofollow" class="external text" href="http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=RssLanding&cat=news&id=2281044">@2</a></span><span style="display:none">Vorlage:Toter Link/investors.celltherapeutics.com</span> <small>(Seite dauerhaft nicht mehr abrufbar, festgestellt im Dezember 2023. <a rel="nofollow" class="external text" href="http://timetravel.mementoweb.org/list/2010/http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=RssLanding&cat=news&id=2281044">Suche in Webarchiven</a>)</small>, PM CTI BioPharma vom 15. Juni 2017, abgerufen am 5. Juli 2017</span>
</li>
<li id="cite_note-17"><span class="mw-cite-backlink"><a href="#cite_ref-17">↑</a></span> <span class="reference-text">Dietmar P. Berger, Rupert Engelhardt, <a href="Roland_Mertelsmann" title="Roland Mertelsmann">Roland Mertelsmann</a>: <i>Das Rote Buch: Hämatologie und Internistische Onkologie.</i> 4. Auflage. Hüthig Jehle Rehm, 2011, ISBN 978-3-609-51216-7, S. 120 (<a rel="nofollow" class="external text" href="https://books.google.de/books?id=E-ZrpuM0UY4C&pg=PA120#v=onepage">eingeschränkte Vorschau</a> in der Google-Buchsuche).</span>
</li>
<li id="cite_note-18"><span class="mw-cite-backlink"><a href="#cite_ref-18">↑</a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=RssLanding&cat=news&id=2327170">CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOX®</a><span style="display:none"><a rel="nofollow" class="external text" href="http://deadurl.invalid/http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=RssLanding&cat=news&id=2327170">@1</a></span><span style="display:none"><a rel="nofollow" class="external text" href="http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=RssLanding&cat=news&id=2327170">@2</a></span><span style="display:none">Vorlage:Toter Link/investors.celltherapeutics.com</span> <small>(Seite dauerhaft nicht mehr abrufbar, festgestellt im Dezember 2023. <a rel="nofollow" class="external text" href="http://timetravel.mementoweb.org/list/2010/http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=RssLanding&cat=news&id=2327170">Suche in Webarchiven</a>)</small>, PM CTI BioPharma vom 18. Januar 2018, abgerufen am 4. Februar 2018</span>
</li>
</ol></div><!--htdig_noindex--><div><div class="zim-footer">
Dieser Artikel wurde von <a class="external text" title="Zuletzt bearbeitet am 2025-04-28" href="https://de.wikipedia.org/wiki/?title=CTI_BioPharma&oldid=255545601">Wikipedia</a> herausgegeben. Der Text ist unter <a class="external text" href="https://creativecommons.org/licenses/by-sa/4.0/deed.de">Creative Commons Attribution-Share Alike 4.0</a> verfügbar, sofern nicht anders angegeben. Für die Mediendateien können zusätzliche Bedingungen gelten.
</div>
</div><!--/htdig_noindex--></div>
</div>
</main>
</div>
</div>
</div>
<script src="./_webp_/webpHandler.js"></script>
</body></html>